Single nucleotide polymorphism-based genome-wide chromosome copy change, loss of heterozygosity, and aneuploidy in barrett's esophagus neoplastic progression

Cancer Prevention Research

Volumn 1, Issue 6, 2008, Pages 413-423

  Li, Xiaohong ^a   Galipeau, Patricia C ^a   Sanchez, Carissa A ^a   Blount, Patricia L ^a   Maley, Carlo C ^b   Arnaudo, Jessica ^a   Peiffer, Daniel A ^c   Pokholok, Dmitry ^c   Gunderson, Kevin L ^c   Reid, Brian J ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b WISTAR INSTITUTE   (United States)

^c ILLUMINA INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOCARCINOMA; AGED; ANEUPLOIDY; ARTICLE; BARRETT ESOPHAGUS; CHROMOSOME 17; CHROMOSOME 9; CHROMOSOME ABERRATION; CROSS-SECTIONAL STUDY; DISEASE COURSE; ESOPHAGUS TUMOR; FEMALE; GENE DOSAGE; GENETIC ASSOCIATION; GENETICS; HETEROZYGOSITY LOSS; HUMAN; HUMAN GENOME; MALE; METHODOLOGY; MIDDLE AGED; PATHOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM;

ADENOCARCINOMA; AGED; ANEUPLOIDY; BARRETT ESOPHAGUS; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 17; CHROMOSOMES, HUMAN, PAIR 9; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; FEMALE; GENE DOSAGE; GENOME, HUMAN; GENOME-WIDE ASSOCIATION STUDY; HUMANS; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 61749087820     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-08-0121     Document Type: Article

References (92)

1. Nowell PC. The clonal evolution of tumor cell populations. Science 1976;194:23-8.
2. Nancarrow DJ, Handoko HY, Smithers BM, et al. Genome-wide copy number analysis in esophageal adenocarcinoma using high-density single-nucleotide polymorphism arrays. Cancer Res 2008;68: 4163-72.
3. Croft J, Parry EM, Jenkins GJ, et al. Analysis of the premalignant stages of Barrett's oesophagus through to adenocarcinoma by comparative genomic hybridization. Eur JGastroenterol Hepatol 2002;14:1179-86.
4. El-Rifai W, Frierson HF, Jr., Moskaluk CA, et al. Genetic differences between adenocarcinomas arising in Barrett's esophagus and gastric mucosa. Gastroenterology 2001;121:592-8.
5. Moskaluk CA, Hu J, Perlman EJ. Comparative genomic hybridization of esophageal and gastroesophageal adenocarcinomas shows consensus areas of DNA gain and loss. Genes Chromosomes Cancer 1998;22:305-11.
6. Cifola I, Spinelli R, Beltrame L, et al. Genomewide screening of copy number alterations and LOH events in renal cell carcinomas and integration with gene expression profile. Mol Cancer 2008;7:6.
7. Gaasenbeek M, Howarth K, Rowan AJ, et al. Combined array-comparative genomic hybridization and single-nucleotide polymorphism-loss of heterozygosity analysis reveals complex changes and multiple forms of chromosomal instability in colorectal cancers. Cancer Res 2006;66:3471-9.
8. Oosting J, Lips EH, van Eijk R, et al. High-resolution copy number analysis of paraffin-embedded archival tissue using SNP BeadArrays. Genome Res 2007;17:368-76.
9. Kloth J N, Oosting J, van Wezel T, et al. Combined array-comparative genomic hybridization and single-nucleotide polymorphism-loss of heterozygosity analysis reveals complex genetic alterations in cervical cancer. BMC Genomics 2007;8:53.
10. Harada T, Chelala C, Bhakta V, et al. Genomewide DNA copy number analysis in pancreatic cancer using high-density single nucleotide polymorphism arrays. Oncogene 2008;27:1951-60.
11. Lindblad-Toh K, Tanenbaum DM, Daly MJ, et al. Loss-of-heterozygosity analysis of small-cell lung carcinomas using single-nucleotide polymorphism arrays. Nat Biotechnol 2000;18:1001-5.
12. Weir BA, Woo MS, Getz G, et al. Characterizing the cancer genome in lung adenocarcinoma. Nature 2007;450:893-8.
13. Lo KC, Bailey D, Burkhardt T, et al. Comprehensive analysis of loss of heterozygosity events in glioblastoma using the 100K SNP mapping arrays and comparison with copy number abnormalities defined by BAC array comparative genomic hybridization. Genes Chromosomes Cancer 2008;47: 221-37.
14. Maley CC, Galipeau PC, Li X, et al. Selectively advantageous mutations and hitchhikers in neoplasms: p16 lesions are selected in Barrett's esophagus. Cancer Res 2004;64:3414-27.
15. Mei R, Galipeau PC, Prass C, et al. Genome-wide detection of allelic imbalance using human SNPs and high-density DNA arrays. Genome Res 2000; 10:1126-37.
16. Tuziak T, Jeong J, Majewski T, et al. High-resolution whole-organ mapping with SNPs and its significance to early events of carcinogenesis. Lab Invest 2005;85:689-701.
17. Lai LA, Paulson TG, Li X, et al. Increasing genomic instability during premalignant neoplastic progression revealed through high resolution array-CGH. Genes Chromosomes Cancer 2007;46: 532-42.
18. Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. JNatl Cancer Inst 2005;97:142-6.
19. Holmes RS, Vaughan TL. Epidemiology and pathogenesis of esophageal cancer. Semin Radiat Oncol 2007;17:2-9.
20. Farrow DC, Vaughan TL. Determinants of survival following the diagnosis of esophageal adenocarcinoma (United States). Cancer Causes Control 1996;7:322-7.
21. Brown LM, Devesa S. Epidemiologic trends in esophageal and gastric cancer in the United States. Surg Oncol Clin N Am 2002;11:235-56.
22. Wang KK, Sampliner RE. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am JGastroen terol 2008; 103:788-97.
23. Anderson LA, Murray LJ, Murphy SJ, et al. Mortality in Barrett's oesophagus: results from a population based study. Gut 2003;52:1081-4.
24. Moayyedi P, Akhtar-Danesh N, Talley NJ, Jankowski J. Mortality risks associated with Barrett's oesophagus: authors' reply. Aliment Pharmacol Ther 2008;27:853-4.
25. Dixon J, Strugala V, Griffin SM, et al. Esophageal mucin: an adherent mucus gel barrier is absent in the normal esophagus but present in columnarlined Barrett's esophagus. Am JG astroenterol 2001;96:2575-83.
26. Jovov B, Van Itallie CM, Shaheen NJ, et al. Claudin- 18: a dominant tight junction protein in Barrett's esophagus and likely contributor to its acid resistance. Am JPh ysiol Gastrointest Liver Physiol 2007;293:G1106-13.
27. Tobey NA, Argote CM, Vanegas XC, Barlow W, Orlando RC. Electrical parameters and ion species for active transport in human esophageal stratified squamous epithelium and Barrett's specialized columnar epithelium. Am JPhysiol Gastrointest Liver Physiol 2007;293:G264-70.
28. Ostrowski J, Mikula M, Karczmarski J, et al. Molecular defense mechanisms of Barrett's metaplasia estimated by an integrative genomics. J Mol Med 2007;85:733-43.
29. Barrett MT, Sanchez CA, Prevo LJ, et al. Evolution of neoplastic cell lineages in Barrett oesophagus. Nat Genet 1999;22:106-9.
30. Maley CC, Galipeau PC, Finley JC, et al. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet 2006;38:468-73.
31. Califano J, van der Riet P, Westra W, et al. Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res 1996;56:2488-92.
32. Califano J, Westra WH, Meininger G, et al. Genetic progression and clonal relationship of recurrent premalignant head and neck lesions. Clin Cancer Res 2000;6:347-52.
33. Lee JJ, Hong WK, Hittelman WN, et al. Predicting cancer development in oral leukoplakia: ten years of translational research. Clin Cancer Res 2000;6: 1702-10.
34. Rosin MP, Cheng X, Poh C, et al. Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. Clin Cancer Res 2000;6: 357-62.
35. Mao L, Lee JS, Fan YH, et al. Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nat Med 1996;2:682-5.
36. Wong DJ, Paulson TG, Prevo LJ, et al. p16 INK4a lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium. Cancer Res 2001;61:8284-9.
37. Eads CA, Lord RV, Wickramasinghe K, et al. Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res 2001;61:3410-8.
38. Maley CC, Galipeau PC, Li X, et al. The combination of genetic instability and clonal expansion predicts progression to esophageal adenocarcinoma. Cancer Res 2004;64:7629-33.
39. Galipeau PC, Cowan DS, Sanchez CA, et al. 17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus. Proc Natl Acad Sci U S A 1996;93:7081-4.
40. Reid BJ, Prevo LJ, Galipeau PC, et al. Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am JGastroenterol 2001;96:2839-48.
41. Dolan K, Morris AI, Gosney JR, Field JK, Sutton R. Loss of heterozygosity on chromosome 17p predicts neoplastic progression in Barrett's esophagus. JGastroenterol Hepatol 2003;18:683-9.
42. Pan H, Califano J, Ponte JF, et al. Loss of heterozygosity patterns provide fingerprints for genetic heterogeneity in multistep cancer progression of tobacco smoke-induced non-small cell lung cancer. Cancer Res 2005;65:1664-9.
43. Galipeau PC, Li X, Blount PL, et al. NSAIDs modulate CDKN2A, TP53, and DNA content risk for future esophageal adenocarcinoma. PLoS Med 2007; 4:e67.
44. McDermott KM, Zhang J, Holst CR, et al. p16 (INK4a) prevents centrosome dysfunction and genomic instability in primary cells. PLoS Biol 2006;4:e51.
45. Barrett MT, Sanchez CA, Galipeau PC, et al. Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus. Oncogene 1996;13:1867-73.
46. Hammoud ZT, Kaleem Z, Cooper JD, et al. Allelotype analysis of esophageal adenocarcinomas: evidence for the involvement of sequences on the long arm of chromosome 4. Cancer Res 1996;56: 4499-502.
47. Dolan K, Garde J, Gosney J, et al. Allelotype analysis of oesophageal adenocarcinoma: loss of heterozygosity occurs at multiple sites. Br JCancer 1998;78:950-7.
48. Reid BJ, Levine DS, Longton G, Blount PL, Rabinovitch PS. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am JGastroenterol 2000;95:1669-76.
49. Rabinovitch PS, Reid BJ, Haggitt RC, Norwood TH, Rubin CE. Progression to cancer in Barrett's esophagus is associated with genomic instability. Lab Invest 1989;60:65-71.
50. Paulson TG, Galipeau PC, Reid BJ. Loss of heterozygosity analysis using whole genome amplification, cell sorting, and fluorescence-based PCR. Genome Res 1999;9:482-91.
51. Reid BJ, Haggitt RC, Rubin CE, Rabinovitch PS. Barrett's esophagus. Correlation between flow cytometry and histology in detection of patients at risk for adenocarcinoma. Gastroenterology 1987; 93:1-11.
52. Blount PL, Galipeau PC, Sanchez CA, et al. 17p allelic losses in diploid cells of patients with Barrett's esophagus who develop aneuploidy. Cancer Res 1994;54:2292-5.
53. Peiffer DA, Le JM, Steemers FJ, et al. High-resolution genomic profiling of chromosomal aberrations using Infinium whole-genome genotyping. Genome Res 2006;16:1136-48.
54. Redon R, Ishikawa S, Fitch KR, et al. Global variation in copy number in the human genome. Nature 2006;444:444-54.
55. Nancarrow DJ, Handoko HY, Stark MS, Whiteman DC, Hayward NK. SiDCoN: a tool to aid scoring of DNA copy number changes in SNP chip data. PLoS ONE 2007;2:e1093.
56. Hsu L, Self SG, Grove D, et al. Denoising arraybased comparative genomic hybridization data using wavelets. Biostatistics 2005;6:211-26.
57. Burrus CS, Gopinath RA, Guo H. Introduction to wavelets and wavelet transforms. New Jersey: Prentice Hall; 1998.
58. Storey JD. A direct approach to false discovery rates. JR Stat Soc Ser B 2002;64:479-98.
59. Li X, Self SG, Galipeau PC, Paulson TG, Reid BJ. Direct inference of SNP heterozygosity rates and resolution of LOH detection. PLoS Comput Biol 2007;3:e244.
60. Pepe MS. The statistical evaluation of medical tests for classification and prediction. United Kingdom: Oxford University Press; 2003, p. 320.
61. Rabinovitch PS, Longton G, Blount PL, Levine DS, Reid BJ. Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables. Am JGastroenterol 2001;96:3071-83.
62. Teodori L, Gohde W, Persiani M, et al. DNA/protein flow cytometry as a predictive marker of malignancy in dysplasia-free Barrett's esophagus: thirteen-year follow-up study on a cohort of patients. Cytometry 1998;34:257-63.
63. Wongsurawat VJ, Finley JC, Galipeau PC, et al. Genetic mechanisms of TP53 loss of heterozygosity in Barrett's esophagus: implications for biomarker validation. Cancer Epidemiol Biomarkers Prev 2006;15:509-16.
64. Florl AR, Schulz WA. Peculiar structure and location of 9p21 homozygous deletion breakpoints in human cancer cells. Genes Chromosomes Cancer 2003;37:141-8.
65. Cairns P, Polascik TJ, Eby Y, et al. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet 1995;11:210-2.
66. Kabat GC, Ng SK, Wynder EL. Tobacco, alcohol intake, and diet in relation to adenocarcinoma of the esophagus and gastric cardia. Cancer Causes Control 1993;4:123-32.
67. Kasahara T, Bilim V, Hara N, Takahashi K, Tomita Y. Homozygous deletions of the INK4a/ARF locus in renal cell cancer. Anticancer Res 2006;26:4299-305.
68. Califano J, Leong PL, Koch WM, et al. Second esophageal tumors in patients with head and neck squamous cell carcinoma: an assessment of clonal relationships. Clin Cancer Res 1999;5:1862-7.
69. Humphray SJ, Oliver K, Hunt AR, et al. DNA sequence and analysis of human chromosome 9. Nature 2004;429:369-74.
70. Park JP, Wojiski SA, Spellman RA, Rhodes CH, Mohandas TK. Human chromosome 9 pericentric homologies: implications for chromosome 9 heteromorphisms. Cytogenet Cell Genet 1998;82: 192-4.
71. Iliopoulos D, Guler G, Han SY, et al. Roles of FHIT and WWOX fragile genes in cancer. Cancer Lett 2006;232:27-36.
72. Lisitsyn NA, Lisitsina NM, Dalbagni G, et al. Comparative genomic analysis of tumors: detection of DNA losses and amplification. Proc Natl Acad Sci U S A 1995;92:151-5.
73. Albrecht B, Hausmann M, Zitzelsberger H, et al. Array-based comparative genomic hybridization for the detection of DNA sequence copy number changes in Barrett's adenocarcinoma. JPa thol 2004;203:780-8.
74. Mueller J, Werner M, Siewert JR. Malignant progression in Barrett's esophagus: pathology and molecular biology. Recent Results Cancer Res 2000;155:29-41.
75. van Dekken H, Vissers CJ, Tilanus HW, Tanke HJ, Rosenberg C. Clonal analysis of a case of multifocal oesophageal (Barrett's) adenocarcinoma by comparative genomic hybridization. JPa thol 1999;188:263-6.
76. Michael D, Beer DG, Wilke CW, Miller DE, Glover TW. Frequent deletions of FHIT and FRA3B in Barrett's metaplasia and esophageal adenocarcinomas. Oncogene 1997;15:1653-9.
77. Kuroki T, Trapasso F, Shiraishi T, et al. Genetic alterations of the tumor suppressor gene WWOX in esophageal squamous cell carcinoma. Cancer Res 2002;62:2258-60.
78. Kuroki T, Yendamuri S, Trapasso F, et al. The tumor suppressor gene WWOX at FRA16D is involved in pancreatic carcinogenesis. Clin Cancer Res 2004;10:2459-65.
79. Aqeilan RI, Kuroki T, Pekarsky Y, et al. Loss of WWOX expression in gastric carcinoma. Clin Cancer Res 2004;10:3053-8.
80. Aqeilan RI, Donati V, Gaudio E, et al. Association of Wwox with ErbB4 in breast cancer. Cancer Res 2007;67:9330-6.
81. Watson JE, Doggett NA, Albertson DG, et al. Integration of high-resolution array comparative genomic hybridization analysis of chromosome 16q with expression array data refines common regions of loss at 16q23-qter and identifies underlying candidate tumor suppressor genes in prostate cancer. Oncogene 2004;23: 3487-94.
82. Pimenta FJ, Cordeiro GT, Pimenta LG, et al. Molecular alterations in the tumor suppressor gene WWOX in oral leukoplakias. Oral Oncol 2007.
83. Thomas T, Abrams KR, De Caestecker JS, Robinson RJ. Meta analysis: cancer risk in Barrett's oesophagus. Aliment Pharmacol Ther 2007;26: 1465-77.
84. Dulai GS, Shekelle PG, Jensen DM, et al. Dysplasia and risk of further neoplastic progression in a regional Veterans Administration Barrett's cohort. Am JGastroenterol 2005;100:775-83.
85. Hage M, Siersema PD, van Dekken H, et al. 5-aminolevulinic acid photodynamic therapy versus argon plasma coagulation for ablation of Barrett's esophagus: a randomised trial. Gut 2004;53: 785-90.
86. Sharma P, Falk GW, Weston AP, et al. Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus. Clin Gastroenterol Hepatol 2006;4:566-72.
87. Wang YH. Chromatin structure of human chromosomal fragile sites. Cancer Lett 2006; 232:70-8.
88. Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer. Nat Rev Genet 2006;7:21-33.
89. van derBurgh A,Dees J,HopWC, van Blankenstein M. Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus. Gut 1996;39:5-8.
90. Solaymani-Dodaran M, Logan RF, West J, Card T. Mortality associated with Barrett's esophagus and gastroesophageal reflux disease diagnoses - a population-based cohort study. Am JGastroenterol 2005;100:2616-21.
91. Jenkins GJ, Doak SH, Parry JM, et al. Genetic pathways involved in the progression of Barrett's metaplasia to adenocarcinoma. Br JSu rg 2002; 89:824-37.
92. Sullivan Pepe M, Etzioni R, Feng Z, et al. Phases of biomarker development for early detection of cancer. JNatl Cancer Inst 2001;93:1054-61.